Mount Sinai’s Blood Test to Detect Antibodies to COVID-19 Receives Emergency Use Authorization From U.S. Food and Drug Administration
Today, the Mount Sinai Laboratory (MSL), Center for Clinical Laboratories received emergency use authorization from the U.S. Food and Drug Administration (FDA) for an antibody test that was developed, validated, and launched at Mount Sinai by a team of internationally renowned researchers …
Krishna J. Patel, PhD, is Awarded the Howard Bremer Scholarship by the Association of University Technology Managers
Krishna J. Patel, PhD, cRTTP, Business Development and Licensing Analyst of Mount Sinai Innovation Partners (MSIP), was awarded the Howard Bremer Scholarship through the Association of University Technology Managers (AUTM). The Scholarship honors emerging professionals bringing creativity and an innovative spirit to …
Meet the Pitch Challenge Contestants: Q&A
As the Mount Sinai Pitch Challenge approaches, we’re excited to introduce the first two teams who will be presenting their healthcare discoveries for a grand prize at this exciting event! These teams won MSIP’s Poster Presentation Competition, where they received a prototyping …
Mount Sinai and Harbour BioMed Collaborate to Advance Novel Biotherapies for the Treatment of Cancer and Coronavirus COVID-19
Collaboration combines Harbour BioMed’s proprietary H2L2 Harbour Mice® platform for fully human monoclonal antibody generation with Mount Sinai’s translational medical research expertise. NEW YORK, NY, CAMBRIDGE, MA, ROTTERDAM, NL, and SUZHOU, CN – Mount Sinai Health System and Harbour BioMed (HBM) have …
Open Innovation with Mount Sinai at the JP Morgan Healthcare Investment Conference
Over 250 healthcare investors, pharma / biotech partners and groundbreaking startups joined Mount Sinai to share successes and strategies that enhance innovation ecosystems last month at the JP Morgan Healthcare Investment Conference in San Francisco. Diversity is key Diversity has become a …
Tacitus Therapeutics Launches in Collaboration with Mount Sinai to Develop Stem Cell Therapies for Life-Threatening Diseases
Tacitus Therapeutics exclusively licenses technology for expansion, differentiation and engineering of hematopoietic stem cells for use in therapeutic applications Tacitus Therapeutics, a clinical-stage company, has launched in collaboration with the Mount Sinai Health System to develop stem cell therapies initially targeting blood …
Life Science Development and the Future of Medicine: The Mount Sinai Perspective
Mount Sinai Innovation Partners (MSIP) participated in several conferences and events to wrap up 2019, gathering thought leaders and industry experts to discuss best practices on building a strong life science ecosystem for the purpose of helping patient populations. These events included …
Nines Debuts Mission to Redefine Radiology, Delivering Next-level Patient Care
Nines’ unique approach to teleradiology reimagines radiology together with engineering and data science prowess to bring a new level of patient care Nines debuts as the first-of-its-kind teleradiology practice that combines top quality radiologists and world-class engineering to deliver high-quality diagnostics and …
Human Immune Monitoring Center at Mount Sinai to Analyze the Effectiveness of a Novel Cancer Therapy Drug
The Human Immune Monitoring Center (HIMC) at the Icahn School of Medicine at Mount Sinai will apply cutting-edge high-throughput technologies to evaluate the therapeutic effects of Libtayo® (cemiplimab-rwlc), a PD-1 antibody blockade developed by biotechnology company Regeneron Pharmaceuticals, Inc and Sanofi. While …
Onegevity Health Acquires Global Licensing Rights to Mount Sinai’s Lab100
Clinic and research lab offers patients access to comprehensive health assessment, expands clinical understanding of disease prevention and provides wealth of health outcomes data Onegevity Health, LLC, a New York City-based health technology company focused on biometric data, artificial intelligence and personalized …